WATCH Yahoo Finance Invest: Our marquee investor conference NasdaqCM - Nasdaq Real Time Price ? USD Eledon Pharmaceuticals, Inc. (ELDN) Follow Compare 4.7400 -0.2200 (-4.44%) As of 2:27 PM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Guggenheim Securities Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 1:30 p.m. ET (10:30 a.m. PT). To register in advance for the presentation webcast, sign up here. A webcast replay will be accessible following the live session on th GlobeNewswire ? 5 days ago ELDN -4.44% Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 per share and (ii) pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of $3.649 per pre-funded warrant. The pre-funded warrants will be immediately exercisable and will have an exercise price of $0.001 per share. The gross pr GlobeNewswire ? 14 days ago ELDN -4.44% Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and is on trajectory for insulin independence - Islet engraftment in the first two subjects with tegoprubart estimated three to five times higher than engraftment in three comparable subjects receiving standard of care tacrolimus-based GlobeNewswire ? 14 days ago ELDN -4.44% Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 8:35 a.m. ET. To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s website under Events. About El GlobeNewswire ? last month ELDN -4.44% Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients Enrollment Completed Four Months Ahead of ScheduleIRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has successfully completed enrollment for its Phase 2 BESTOW clinical trial, which is designed to assess the safety and efficacy of its investigational immunosuppression therapy tegoprubart for the prevention of organ rejection in patients undergoing kidney transplantation. The trial reached its target enrollment of 12 GlobeNewswire ? 2 months ago ELDN -4.44% Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported recent business highlights f GlobeNewswire ? 2 months ago ELDN -4.44% Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection 80 Participants (Two-thirds of Projected Recruitment) EnrolledIRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. “As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America,” said D GlobeNewswire ? 3 months ago ELDN -4.44% Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, 2024, in Boston, MA. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threaten GlobeNewswire ? 4 months ago ELDN -4.44% Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m2 Mean eGFR measured above 60 mL/min/1.73m2 at all reported time points after day 30 post-transplant IRVINE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today presented updated data from the Company’s ongoing open GlobeNewswire ? 5 months ago ELDN -4.44% Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation Tegoprubart used as part of immunosuppressive treatment following the first-ever kidney xenotransplant IRVINE, Calif., May 09, 2024 ( GlobeNewswire ? 6 months ago ELDN -4.44% Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will present a poster that features updated data from Eledon’s ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of rejection in patients undergoing kidney transplantation. Details GlobeNewswire ? 6 months ago ELDN -4.44% Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the first participant in an investigator-led clinical tr GlobeNewswire ? 6 months ago ELDN -4.44% Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has entered into a securities purchase agreement with certain institutional and accredited healthcare investors for a private investment in public equity financing that is expected to result in gross proceeds of approximately $50 million, before deducting offering expenses. Pursuant to the terms of the securities purchase agreement, Eledon is selling an aggregate of 13, GlobeNewswire ? 6 months ago ELDN -4.44% Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average p GlobeNewswire ? 7 months ago ELDN -4.44% Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation. “We are pleased with the strong pace of enrollment in our Phase 2 BESTOW trial and believe it speaks to the underlying demand for a new immunosuppressive regimen fo GlobeNewswire ? 7 months ago ELDN -4.44% Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human Historic kidney xenotransplantation procedure conducted at Massachusetts General Hospital Tegoprubart administration has now been used investigationally to prevent rejection in both kidney and heart pig-to-human xenotransplantations, as well as in human-to-human kidney transplantation Eledon recently presented results from its ongoing Phase 1b kidney transplantation study which demonstrated that tegoprubart was generally safe and well tolerated and successfully prevented rejection with post-tran GlobeNewswire ? 7 months ago ELDN -4.44% Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company’s Compensation Committee granted 42,500 restricted stock units (RSUs) and stock options to purchase an aggregate of 90,000 common shares, at a per share exercise price of $1.77, the closing price of Eledon’s common stock on the grant date, to one employee. The RSUs and stock options were granted as inducements material to the new employee entering employment w GlobeNewswire ? 8 months ago ELDN -4.44% Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated Dosed first participants in Phase 2 BESTOW trial in kidney transplantation Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced a summary of 2023 accomplish GlobeNewswire ? 10 months ago ELDN -4.44% Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely? There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... Simply Wall St. ? 10 months ago ELDN -4.44% Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming NobleCon19 - Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4, 2023, at 12:00 p.m. EST. Dr. Gros will also participate in a panel discussion titled: The Organ Transplant Revolution, that will take place on Monday, December 4, 20 GlobeNewswire ? 11 months ago ELDN -4.44% Performance Overview Trailing total returns as of 11/12/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ELDN S&P 500 YTD +163.33% +25.71% 1-Year +308.62% +35.81% 3-Year -4.24% +28.97%
